Nektar Therapeutics NKTR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's operating income?
- Nektar Therapeutics (NKTR) reported operating income of -$39.05M in Q1 2026.
- How has Nektar Therapeutics's operating income changed year-over-year?
- Nektar Therapeutics's operating income increased by 12.3% year-over-year, from -$44.54M to -$39.05M.
- What is the long-term trend for Nektar Therapeutics's operating income?
- Over 3 years (2021 to 2025), Nektar Therapeutics's operating income has grown at a -32.0% compound annual growth rate (CAGR), from -$446.1M to -$140.1M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.